Easy Care Ltd, Israel

Analgesic, Antipyretic. Paracetamol 1 g / 6.7 ml.
AMP. (sol. for IV infus.): 3×6.7ml. Child./ adolesc./adults 33 - 50 kg :15 mg/ kg up to four times/d. Max. dly. dose is 60 mg/kg of bdy. wt., max. dly dose 3g. Child. 10-33 kg (approx. 1-11 yrs. old): 15 mg/kg up to four times/d. Max. dly. dose is 60 mg/kg of bdy. wt., max. 2g. Newborns (full term)/ infants up to 10kg: 7.5 mg/kg up to four times/d. max. dly. dose is 30 mg/kg of bdy. wt. Adolesc./adult. >50 kg: 1 g up to four times /d. max. dly dose must not exceed 4g.
Short-term tmt. of moder. pain, especially follow. surg. and for the short-term tmt. of fever, when administ. by IV route is clinic. justified by an urgent need to treat pain or hyperthermia and/or when other routes of administ. are not possible.
C/I: Hypersens., severe hepatocellular insuffic./ severe active liver dis.

Somatostatin Analog. Octreotide 0.1 mg/ml, 0.5 mg/ml.
AMP.Sol. for inj/inf. 10X 1 ml  for SC/IV
Acromegaly Initially 0.05 to 0.1 mg by s.c.inject. every 8 or 12 hours. Dosage adjustm. should be based on monthly assessment of GH and IGF-1 levels (target: GH<2.5 ng/mL; IGF-1 within normal range) and clin. sympt., and on tolerability. In most pts, the optimal dly dose will be 0.3 mg. A max. dose of 1.5 mg /d should not be exceeded. For pts on a stable dose, assessment of GH should be made every 6 months. If no relevant reduct. in GH levels and no improvement in clin. sympt. have been achieved within 3 months of tmt. with this drug, ther. should be discontinued.
Gastro-entero-pancreatic endocrine tumours Initially 0.05 mg once or twice/d by s.c. inject. Depending on clin. respon., effect on levels of tumour-produced hnes. (in cases of carcinoid tumours, on the urinary excretion of 5-hydroxyindole acetic acid), and on tolerability, dosage can be gradually incr. to 0.1 to 0.2 mg 3 times/d. Under exceptional circumstances, higher doses may be req. Maint. doses have to be adjusted individually. In carcinoid tumours, if there is no beneficial respon. within 1 week of tmt. with this drug at the max toler. dose, ther. should not be continued.
Complications following pancreatic surgery 0.1 mg 3 times/d by s.c. inj. for 7 consecutive days, starting on the day of operation at least 1 hour before laparotomy.
Bleeding gastro-oesophageal varices 25 micrograms/h for 5 d by continuous i.v. infusion. This drug can be used in dilution with physiological saline. In cirrhotic pts with bleeding gastro-oesophageal varices, this drug has been well tolerat. at continuous i.v. doses of up to 50 micrograms/h for 5 days.
Prevention of complicat. following pancreatic surgery. Symptomatic control and reduction of GH and IGF-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. This treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. Relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - Carcinoid tumours with features of the carcinoid syndrome - VIPomas - Glucagonomas - Gastrinomas / zollinger-Ellison syndrome usually in conjunction with proton pump inhibitors or H2- antagonist therapy - Insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - GRFomas. This drug is not an antitumour therapy and is not curative in these patients. Emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.
C/I: Hypersens.

Antifibrinolytic. Tranexamic Acid 500 mg / 5ml.
AMP. ( sol. for inj.): 5×5 ml.
Adult.: The recomm. standard dosage: 5-10 ml IV, at a rate of 1 ml/min., 2-3 times dly. General Fibrinolysis: 10 ml I.V., 3-4 times dly. Prostatectomy: 5-10 ml by slow I.V. inj., every 8 hrs. (The 1st dose being admin. during the operat.), for the first 3 days follow. surg. When required, oral tmt. with tranexamic acid may be follow. Dental Surg.: Factor VIII or IX concentrates and Tranexamic Acid 10 mg/kg bdy. wt. should be admin. IV immediate. before surg. When required, oral tmt. with tranexamic acid may be followed. Epistaxis: may be applied topical. to the nasal mucosa, either using a spray or by soaking a gauze strip in the sol. and then packing the nasal cavity. Child. : Dosage should be calculated accord. to bdy. wt., 10 mg/kg I.V.
General fibrinolysis. This may occur in prostatic and pancr. carcinoma follow. thoracic surg. and other major operat. proced., in obstetr. complic. such as abruptio placentae and post-partum
hemorrhage, in connect. with thrombolytic ther., and in init. and follow-up tmt. follow. prostatectomy and bladder surg. Prior to, and follow., dental surg. in hemophiliacs. Epistaxis.
C/I: Hypersens. Acute venous/ arter. thrombosis. Fibrinolytic condit. follow. consumpt. coagulopathy except in those with predominant activation of the fibrinolytic systemwith acute severe bleed. Severe renal impair. (risk of accumul.). History of convuls. Intrathecal, intraventr. inject., intracereb. application (risk of cerebr. edema and convuls.).